Introduction
Due to demographic changes the number of patients with multimorbidity is continuously increasing in western countries. One of the associated disorders is the chronic wound. This includes a rise in the incidence of impaired wound healing, causing a reduced patients' quality of life and rising health care costs. Conventional therapies of chronic wounds are increasingly reaching their limits, motivating the search for alternative treatment options, including stem cell-based therapies 1 . This paper discusses the recent in vitro and in vivo results of adipose-derived stem cells (ASCs) in wound healing.
Physiological wound healing
Wound healing is a complex biological process consisting of the four different but partially overlying steps coagulation, inflammation, formation of granulation tissue (proliferative phase) and remodelling or scar formation.
After injury, initiation of a bloodclotting cascade prevents excessive bleeding and provides temporary protection of the wound area. During this process platelet-derived growth factor and transforming growth factors A1 and 2 (TGF-A1 and TGF-2) are released, causing attraction of inflammatory cells such as leukocytes and macrophages.
Within a few days after injury, apoptosis of inflammatory cells occurs. Anti-inflammatory cytokines such as TGF-A1 and Interleukin (IL) 1 as well as bioactive lipids are assumed to be involved in this process ( Figure 1 ).
In the following proliferative phase, production of growth factors and activation of dermal and epidermal cells lead to new tissue formation. Endothelial progenitor cells, which are essential for physiological wound healing, are mobilised by nitric oxide, vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP9). Formation of extra-cellular matrix (ECM)-rich tissue occurs in response to stromal cell-derived factor (SDF)-1 and insulin-like growth factor (IGF).
In the last step of wound healing, matrix remodelling and/or scar formation through cellular migration, proliferation and angiogenic induction is initiated by TGF-A, MMPs and tumour necrosis factor (TNF) 2 .
Impaired wound healing
A chronic wound is defined as a wound that does not heal in a certain period of time in spite of appropriate therapy. However, the exact-time point is in discussion. Most authors refer to a chronic wound as a wound that exists for more than three months 3 . Impaired wound healing is associated with senescence, ischaemia and bacterial colonisation. 4, 5, 7 .
Discussion
The authors have referenced some of their own studies in this review. The protocols of these studies have been The processes of physiological and impaired wound healing and some of the involved factors are represented schematically. In contrast to an acute wound (left side) the chronic wound (right side) is characterised by a persistent inflammation as well as an impaired extra-cellular matrix synthesis and neovascularisation which lead to an impaired healing process. EPC, endothelial progenitor cell; FGF, fibroblast growth factor; IGF, insulin-like growth factor; IL, Interleukin; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; ROS, reactive oxygen species; TGF, transforming growth factors; TNF, tumour necrosis factor; VEGF vascular endothelial growth factor. tissue maceration, ingrown foreign objects and others. Chronic diseases such as diabetes, renal failure or cancer as well as congenital disorders, smoking, alcoholism, drugs, uraemia and nutritional deficiencies are systemic factors which also cause impaired wound healing. Venous ulcers, pressure ulcers and diabetic ulcers are the most common types of chronic wounds, representing 90% of all chronic wounds 14 generated a living dressing system. They encapsulated human ASCs in situ in a water-soluble, thermo responsive hyper-branched polyethylene glycol-based copolymer. Cell viability in this hydrogel was high for up to 7 days under cell culture conditions. While cellular secretion of growth factors such as VEGF and placental-derived growth factor production increased over 7 days, cellular proliferation was inhibited and IL-2 and IFNγ release were unaffected 14 . In a recent study it has been shown that the bacterial strains Escherichia coli, Staphylococcus aureus healing processes via paracrine mechanisms as well as fusion and differentiation, for example, into keratinocytes or fibroblasts [8] [9] [10] .
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. An overview of ASC functions in wound healing is summarised in Figure 2. approved by the relevant ethics committees related to the institution in which they were performed.
Chronic wounds are a rising problem in daily clinical routine. As conventional treatment strategies often fail, stem cell-based therapies have been investigated over the last decade. Recent in vitro and in vivo studies have shown that ASCs are a desirable alternative to embryonic or bone marrow-derived stem cells.
ASCs have already been shown to have a positive impact on wound healing, as they are attracted to the wound site and influence wound 
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improve ASC motility, retention and proliferation
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Limitations of the use of adiposederived stem cells
Donor specificity is a well-known phenomenon. Recent studies have investigated ASC function in the context of donor's age and gender. Guercio et al. 26 have shown a higher proliferation capacity of ASCs of younger dogs than older animals. Donor specificity of human ASCs has been shown by Shu et al. 27 , who observed a relation of donor age and cell differentiation as well as anti-apoptosis ability. Another study with human ASCs showed that, independently from donor's age, equal amounts of ASCs could be isolated. However, infant-derived cells showed different morphology and enhanced angiogenic and osteogenic capabilities 28 . So far, there is little evidence on the effects of gender on ASC potential. Fossett and Khan 29 summarised that females have a significantly higher yield of MSCs than males and that oestrogens have an excitatory role controlling levels of cytokines and growth factor production 29 . Moreover, gender of ASC donors influenced the proliferation, differentiation, paracrine and anti-apoptosis abilities of human ASCs 27 . Besides age and gender, body mass index, chronic diseases, western lifestyle and many other features cause donor-specific differences. For progenitor cells it has been shown that cells harvested from patients with chronic diseases have a reduced regenerative potential 30, 31 . Whether these individual factors have an influence of the regeneration potential of ASC is still unclear and has to be focused in future studies.
ASCs from streptozotocin-induced type 1 diabetic mice showed a decreased proliferate potential and reduced migration. Additionally, a reduction of stem cell marker-positive cells was shown. The release of the treatment with ASCs initiated smaller wound sizes and was associated with the development of new blood vessels 20 .
Recent clinical studies
Since the end of 19th century autologous transplantation of fatty tissue was used as filler in plastic surgery. A continuous improvement of methods and purification of material through specific centrifugation protocols increased the predictability and stability of results. Techniques based on the use of stem cell niches from adipose tissue are already important applications in plastic and cosmetic surgery 21 . Gir et al. 22 listed 174 published cases of clinical applications of ASCs in plastic surgery involving soft-tissue augmentation, wound healing and tissue engineering. No adverse effects have been reported in these studies.
Akita et al. 23 described the successful use of non-cultured autologous ASCs for treatment of chronic radiation injury. In the excised irradiated skin defect ASCs were applied together with bFGF and an artificial dermis.
Improving aspects for adiposederived stem cells
Jiang et al. 24 demonstrated that a surface carrier of medical-grade silicone coated by plasma polymerisation with a thin layer of acrylic acid allows high-efficiency transfer of ASCs to wounds in an in vivo murine model. ASCs delivered by the carrier significantly accelerated wound healing similar to those delivered by intradermal injection 24 .
To improve their therapeutic potential, ASCs were genetically modified. Treated cells showed an extended proliferation period, an increased secretion of VEGF, a higher migration potential and after, injection into a mouse wound model, a promoted wound healing 25 . Furthermore, overexpression of the SDF-1 receptor CXCR4 has been shown to and Streptococcus pyogenes have no considerable cytotoxic effects on ASCs. Exposure of ASCs to these bacteria and their components has no negative effect on ASC proliferation. Therefore Fiedler et al. 15 presumed, that ASCs can support wound healing even at bacterially infected wound sites.
Recent work in vivo
In an animal-based model it has already been shown that transplanted MSCs can migrate to impaired tissues and activate regeneration processes 16 . Hong et al. 17 showed in a rabbit ear in vivo model that topically delivered rabbit ASCs are engrafted and proliferate in wounds, where they exhibited an activated fibroblast phenotype. Furthermore, ASCs led to increased endothelial cell and macrophage recruitment. In contrast to bone marrow-derived MSCs and dermal fibroblasts they increased granulation tissue formation 17 . Improved skin regeneration after ASC transplantation in vivo has been shown by Sheng et al. 18 correspondingly. The presence of ASCs induced expression of epidermal and VEGF and increased cell proliferation and neovascularisation. The regenerated skin was much thicker compared with controls. The transplanted ASCs were detectable in subcutaneous tissue, vascular vessels and hair follicles for 4 weeks 18 . Similar to healthy animal models positive effects of ASCs on wound healing could also be shown for animals with chronic diseases or artificially induced impaired wound healing. As, consequence of ASC transfer an increase in capillary density, collagen intensity, VEGF and TGF-β3 expression was displayed. Animals with autologous ASC transplantation on wounds showed significantly increased survival, angiogenesis and epithelialisation 19 . ASCs accelerated wound healing of radiation ulcers in a modified rat model, where they were co-localised with endothelial cell markers in ulcerated tissues. The Because the use of ASCs in wound healing applications is still limited by a lack of clinical data, further studies have to pave the way for their routine clinical application.
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Another influencing factor on ASC applicability in chronic wound treatment is the composition of wound fluid, which significantly differs between acute and chronic wounds. In an in vitro wound model they have been shown to influence ASCs function inversely. Whereas AWF has a strong chemotactic impact and stimulates ASC proliferation, CWF has an inhibiting effect on ASC migration and proliferation. CWF strongly induces expression of bFGF, VEGF and MMP9 33 .
Further aspects on practicality of ASC application are handling and commercialisation, which are difficult as seen from the industrial side. Moreover, the risk of inducing cancer by transplantation of ASCs is not fully excluded yet 11 ( Figure 2 ).
Future aspects
Currently, there are no standardised protocols for the clinical application of ASCs and no consensus of the number of cells is required for different treatment options. To ensure the safety and efficacy of ASC application standardised protocols and larger randomised controlled trials are needed 22 . Furthermore, donor specificity has to be investigated in detail and the underlying reasons of different efficacy have to be elucidated. However, within the scope of personalised medicine, application of autologous ASCs in chronic wound treatment has to be considered individually.
Conclusion
MSCs derived from adipose tissue, called ASCs, are a promising alternative to embryonic or bone marrowderived stem cells in the therapy of chronic wounds. They are less invasive to harvest, migrate to the wound site through paracrine effects and catalyse wound healing via paracrine
